Pretax profits in the first quarter of 1995 at Norwegian company Hafslund Nycomed amounted to 456 million Norwegian kroner ($73 million), 51% ahead of the like, year-earlier period and well up on expectations. Operating profits before R&D costs were 774 million kroner, up 48.8%. There was an increase of 42.1% in earnings per share to 3.07 kroner in the first quarter, and revenues grew 45.2% to 2.4 billion kroner.
Analysts at Goldman Sachs have raised their rating of the company's shares to market outperformer from market performer. They see Hafslund's key dynamic as being the underlying imaging sales growth, which they expect to advance 4%-6%, having previously forecast 2%-4%.
Nycomed Imaging had operating profits of 607 million kroner, up 65.8% in the first quarter of 1995. Imaging revenues were 1.3 billion kroner, more than double revenues in the like, year-earlier period. Both results were higher than analysts' expectations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze